Replies to post #223128 on Biotech Values

[DewDiligence]

There’s ordinary K-M censoring—what you just described—but there’s another kind of censoring, informally speaking. We’ve all seen data presentations that exclude troublesome data points based on some post hoc criterion, and such cherry-picking may be described to an investor audience as a form of censoring.

[mcbio]

No, censoring is normal in any Kaplan-Meier curve - it just means they haven't followed the patient for long enough yet (and there has been no event with that patient).

Thus if a patient started the trial only the day before the date of the graph, they would be shown as censored after 1 day.

(Remember K-M graphs pretend everyone starts the trial at the same time).

You can read more about it here:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932959/

Thanks to you and the others chiming in on this. Very helpful!